PR Newswire Clinical TrialsOriginal article
AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171
Trial StartAHB-171Positive
AI Analysis
Summary
AusperBio announced the first patient dosed in a clinical study of AHB-171, an investigational oligonucleotide therapeutic candidate for chronic hepatitis B treatment.
Clinical Trial Data
Outcome Details
First patient dosed in clinical study
Importance:5/10
Sentiment:
0.50
hepatitis Boligonucleotide therapeuticsclinical trialfirst patient dosed
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 3, 2026 9:30 AM